Bills · HR 6321
IN COMMITTEE· 119TH CONGRESS
House BillHR 6321Health
Lung Cancer Medicare Access to Precise Testing Act
INTRO NOV 28· LAST ACTION NOV 28
READING
2MIN
COSPONSORS
3BIPARTISAN
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenVoters should care about this bill because it directly impacts access to advanced cancer diagnostics and the financial burden of healthcare for seniors. Lung cancer is a leading cause of cancer death, and modern medicine has developed targeted therapies that work best when doctors understand the specific genetic or molecular profile of a patient's tumor. These biomarker tests are crucial for identifying which patients will benefit most from particular treatments.
If this bill becomes law, it would ensure that all Medicare beneficiaries with lung cancer have access to these tests without financial barriers, potentially leading to more effective and personalized treatment plans, and improved health outcomes. Without this law, coverage for these tests might remain inconsistent or require significant out-of-pocket costs, limiting access to advanced care for some patients and adding to their financial strain during a challenging time.
KEY PROVISIONS
4AI-extractedPROVISION 01
Requires Medicare to cover lung cancer biomarker testing for individuals diagnosed with lung cancer.
This ensures these specific advanced diagnostic tests are included as a standard benefit under Medicare.
PROVISION 02
Mandates that Medicare pay 100 percent of the reasonable charges for lung cancer biomarker testing.
This eliminates out-of-pocket costs for beneficiaries for these specific tests, making them entirely free for eligible patients.
PROVISION 03
Defines 'lung cancer biomarker testing' as tests identifying specific biomarkers (like genes or proteins) from a patient's tissue, blood, or bodily fluids.
This provides a clear scope for what specific tests are covered by the bill's provisions.
PROVISION 04
Establishes an effective date of January 1, 2027, for the coverage of these tests.
This sets a specific timeline for when the new coverage and payment rules will begin.
SPONSORSHIP
1 + 3
D· New Jersey
YRS IN OFFICE
9
BILLS LED
93
COSPONSOR BREAKDOWNBIPARTISAN · 66%
DEM 2 REP 1 IND 0
ACTION TIMELINE
2 EVENTSNOV 28
Introduced in House
NOV 28
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
BILL INFO
TypeHouse Bill
NumberHR 6321
Congress119th
StatusIn Committee
IntroducedNov 28, 2025
Last actionNov 28, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · WAYS AND MEANS COMMITTEE · INTRODUCED NOV 28, 2025
House BillHR 6321Health
Lung Cancer Medicare Access to Precise Testing Act
INTRODUCED NOV 28, 2025· LAST ACTION NOV 28, 2025
PASSAGE CHANCES
—%
READING
2 min
COSPONSORS
3
COMPLEXITY
Moderate
